{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T07:03:59Z","timestamp":1772435039644,"version":"3.50.1"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pharmacogenomic (PGx) variants can influence drug efficacy and safety, yet their prevalence in Latin American populations with cancer is underexplored. Our aim is to characterize the frequency and phenotypic distribution of actionable pharmacogenes in Brazilian patients with metastatic prostate cancer (MPC) and Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer (BC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This analysis included 452 patients (259 BC, 193 MPC) from a multicenter study across 19 Brazilian sites. Exome sequencing was performed, and PGx variants were analyzed using the Pharmacogenomics Clinical Annotation Tool (PharmCAT) following the Clinical Pharmacogenetics Implementation Consortium (CPIC\u00ae) guidelines. Genotypes, star alleles, and predicted phenotypes were reported for 15 clinically relevant pharmacogenes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Actionable PGx phenotypes were detected in 99.33% of participants. The decreased-function\n                      <jats:italic>ABCG2<\/jats:italic>\n                      rs2231142 T allele occurred at 8.96%, and the\n                      <jats:italic>VKORC1<\/jats:italic>\n                      rs9923231 T allele at 32.63%. In\n                      <jats:italic>SLCO1B1<\/jats:italic>\n                      , normal function predominated (63.11%), with 21.11% exhibiting decreased function. Normal metabolizer phenotypes were most frequent in\n                      <jats:italic>CYP2C19<\/jats:italic>\n                      (45.35%),\n                      <jats:italic>CYP2C9<\/jats:italic>\n                      (70.51%), and\n                      <jats:italic>CYP3A4<\/jats:italic>\n                      (94.62%), whereas\n                      <jats:italic>CYP2B6<\/jats:italic>\n                      was dominated by intermediate metabolizers (43.02%) and\n                      <jats:italic>CYP3A5<\/jats:italic>\n                      by poor\/intermediate metabolizers (93.79%). Normal diplotypes predominated in thiopurine-related genes (\n                      <jats:italic>NUDT15<\/jats:italic>\n                      : 92.92%;\n                      <jats:italic>TPMT<\/jats:italic>\n                      : 88.72%), although nonfunctional alleles were observed. In\n                      <jats:italic>UGT1A1<\/jats:italic>\n                      , decreased-function alleles accounted for approximately 37% of participants. Clinically relevant\n                      <jats:italic>DPYD<\/jats:italic>\n                      and\n                      <jats:italic>RYR1<\/jats:italic>\n                      variants were rare (&amp;lt;2.0%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Nearly all Brazilian patients with cancer carried at least one actionable PGx variant, highlighting the potential impact of PGx-guided therapy in oncology. These results underscore the value of integrating pharmacogenomic strategies into clinical practice in Brazil.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1736887","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T06:35:49Z","timestamp":1772433349000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of actionable pharmacogenomic variants in Brazilian patients with cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Jaqueline B.","family":"Schuch","sequence":"first","affiliation":[{"name":"Hospital Moinhos de Vento","place":["Porto Alegre, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana R.","family":"Botton","sequence":"additional","affiliation":[{"name":"Hospital de Cl\u00ednicas de Porto Alegre","place":["Porto Alegre, Brazil"]},{"name":"Universidade Federal do Rio Grande do Sul, Programa de P\u00f3s-Gradua\u00e7\u00e3o em Gen\u00e9tica e Biologia Molecular","place":["Porto Alegre, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ang\u00e9lica C.","family":"De Baumont","sequence":"additional","affiliation":[{"name":"Hospital Moinhos de Vento","place":["Porto Alegre, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovana","family":"Curzel","sequence":"additional","affiliation":[{"name":"Hospital Moinhos de Vento","place":["Porto Alegre, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan A.","family":"Cadore","sequence":"additional","affiliation":[{"name":"Hospital Moinhos de Vento","place":["Porto Alegre, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e1udia","family":"Bordignon","sequence":"additional","affiliation":[{"name":"Hospital Moinhos de Vento","place":["Porto Alegre, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahira L.","family":"Rosa","sequence":"additional","affiliation":[{"name":"Hospital Moinhos de Vento","place":["Porto Alegre, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitor F.","family":"Vasconcellos","sequence":"additional","affiliation":[{"name":"Hospital Universit\u00e1rio Cassiano Ant\u00f4nio Moraes","place":["Vit\u00f3ria, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilian A. R.","family":"Barros","sequence":"additional","affiliation":[{"name":"Instituto Brasileiro de Controle do C\u00e2ncer","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiano P.","family":"Souza","sequence":"additional","affiliation":[{"name":"Hospital de C\u00e2ncer de Barretos","place":["Barretos, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Williams F.","family":"Barra","sequence":"additional","affiliation":[{"name":"N\u00facleo de Pesquisas em Oncologia, Universidade Federal do Par\u00e1","place":["Bel\u00e9m, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela L. C.","family":"Louzeiro","sequence":"additional","affiliation":[{"name":"Hospital de Oncologia Dr. Tarquinio Lopes Filho","place":["S\u00e3o Lu\u00eds, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Notari","sequence":"additional","affiliation":[{"name":"Hospital Escola da Universidade Federal de Pelotas\/Empresa Brasileira de Servi\u00e7os Hospitalares (EBSERH)","place":["Pelotas, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana J.","family":"de Menezes","sequence":"additional","affiliation":[{"name":"Hospital Nossa Senhora da Concei\u00e7\u00e3o","place":["Porto Alegre, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro E. R.","family":"Liedke","sequence":"additional","affiliation":[{"name":"Hospital de Cl\u00ednicas de Porto Alegre","place":["Porto Alegre, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gl\u00e1ucio A.","family":"Bertollo","sequence":"additional","affiliation":[{"name":"Associa\u00e7\u00e3o Feminina de Educa\u00e7\u00e3o e Combate ao C\u00e2ncer (AFECC), Hospital Santa Rita de C\u00e1ssia","place":["Vit\u00f3ria, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline B. L.","family":"Gongora","sequence":"additional","affiliation":[{"name":"Hospital do C\u00e2ncer UOPECCAN","place":["Cascavel, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrique G.","family":"Ascenco","sequence":"additional","affiliation":[{"name":"Hospital Universit\u00e1rio Maria Aparecida Pedrossian","place":["Campo Grande, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Kowalski-Neto","sequence":"additional","affiliation":[{"name":"Hospital Calixto Midlej Filho, Santa Casa de Miseric\u00f3rdia de Itabuna","place":["Itabuna, Brazil"]},{"name":"Faculdade de Medicina, Universidade Estadual de Santa Cruz","place":["Ilh\u00e9u, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina P.","family":"Oppermann","sequence":"additional","affiliation":[{"name":"Hospital F\u00eamina","place":["Porto Alegre, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Werutsky","sequence":"additional","affiliation":[{"name":"Hospital S\u00e3o Lucas PUCRS","place":["Porto Alegre, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edilmar M.","family":"Santos","sequence":"additional","affiliation":[{"name":"Liga Norte Riograndense Contra o C\u00e2ncer","place":["Natal, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavio S.","family":"Brand\u00e3o","sequence":"additional","affiliation":[{"name":"Santa Casa de Belo Horizonte","place":["Belo Horizonte, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruffo","family":"Freitas-Junior","sequence":"additional","affiliation":[{"name":"Hospital do C\u00e2ncer Ara\u00fajo Jorge da Associa\u00e7\u00e3o de Combate ao C\u00e2ncer em Goi\u00e1s","place":["Goi\u00e2nia, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ang\u00e9lica","family":"Nogueira-Rodrigues","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais","place":["Belo Horizonte, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 L. C.","family":"Mancini","sequence":"additional","affiliation":[{"name":"Hospital Universit\u00e1rio Get\u00falio Vargas","place":["Manaus, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Bessel","sequence":"additional","affiliation":[{"name":"Hospital Moinhos de Vento","place":["Porto Alegre, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel S.","family":"Macedo","sequence":"additional","affiliation":[{"name":"Hospital Moinhos de Vento","place":["Porto Alegre, Brazil"]},{"name":"Instituto D'Or de Pesquisa e Ensino (IDOR)","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela D.","family":"Rosa","sequence":"additional","affiliation":[{"name":"Hospital Moinhos de Vento","place":["Porto Alegre, Brazil"]},{"name":"Hospital de Cl\u00ednicas de Porto Alegre","place":["Porto Alegre, Brazil"]},{"name":"Faculdade de Medicina, Universidade Federal do Rio Grande do Sul","place":["Porto Alegre, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3389\/fphar.2020.00445","article-title":"Toxicity and pharmacogenomic biomarkers in breast cancer chemotherapy","volume":"11","author":"Al-Mahayri","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1101\/gr.094052.109","article-title":"Fast model-based estimation of ancestry in unrelated individuals","volume":"19","author":"Alexander","year":"2009","journal-title":"Genome Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/life12010048","article-title":"Comparison of anticancer drug toxicities: Paradigm shift in adverse effect profile","volume":"12","author":"Basak","year":"2021","journal-title":"Life"},{"key":"B5","doi-asserted-by":"publisher","first-page":"eaay5012","DOI":"10.1126\/science.aay5012","article-title":"Insights into human genetic variation and population history from 929 diverse genomes","volume":"367","author":"Bergstr\u00f6m","year":"2020","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1178715","DOI":"10.3389\/fphar.2023.1178715","article-title":"Characterization of pharmacogenomic variants in a Brazilian admixed cohort of elderly individuals based on whole-genome sequencing data","volume":"14","author":"Bertholim-Nasciben","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/cpt.3702","article-title":"Prevalence of actionable pharmacogenetic genotype frequencies, cautionary medication use, and polypharmacy in community\u2010dwelling older adults","volume":"118","author":"Bousman","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/cpt.350","article-title":"Genetic variation among 82 pharmacogenes: the PGRNseq data from the eMERGE network","volume":"100","author":"Bush","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/cpt.2557","article-title":"The clinical pharmacogenetics implementation consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms","volume":"111","author":"Cooper\u2010DeHoff","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"101197","DOI":"10.1016\/j.esmoop.2023.101197","article-title":"Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe","volume":"8","author":"De With","year":"2023","journal-title":"ESMO Open"},{"key":"B11","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gkz836","article-title":"The international genome sample resource (IGSR) collection of open human genomic variation resources","volume":"48","author":"Fairley","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B12","unstructured":"Safety announcement: FDA highlights importance of DPD deficiency discussions with patients prior to capecitabine or 5FU treatment\n          \n          \n          2025"},{"key":"B13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/cpt.910","article-title":"The pharmacogene variation (PharmVar) consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database","volume":"103","author":"Gaedigk","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/cpt.269","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for UGT1A1 and Atazanavir prescribing","volume":"99","author":"Gammal","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40262-015-0283-1","article-title":"Pharmacokinetic drug interaction studies with enzalutamide","volume":"54","author":"Gibbons","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"B16","article-title":"Powering genomic analysis, at every scale","year":"2025"},{"key":"B17","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00280-021-04307-0","article-title":"Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients","volume":"88","author":"Helsby","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10549-022-06596-2","article-title":"Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark","volume":"194","author":"Hjorth","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e70009","DOI":"10.1111\/cts.70009","article-title":"Prevalence of actionable pharmacogenetic variants and high\u2010risk drug prescriptions: a Swiss hospital\u2010based cohort study","volume":"17","author":"Hodel","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/s41588-023-01415-w","article-title":"Accurate rare variant phasing of whole-genome and whole-exome sequencing data in the UK Biobank","volume":"55","author":"Hofmeister","year":"2023","journal-title":"Nat. Genet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2147\/CEG.S206194","article-title":"Association of IFNL3 rs12979860 polymorphism with HCV-related hepatocellular carcinoma susceptibility in a Chinese population","volume":"12","author":"Hou","year":"2019","journal-title":"Clin. Exp. Gastroenterol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jmoldx.2016.01.003","article-title":"Preemptive pharmacogenomic testing for precision medicine","volume":"18","author":"Ji","year":"2016","journal-title":"J. Mol. Diagn."},{"key":"B23","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/cpt.668","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics\u2010guided warfarin dosing: 2017 update","volume":"102","author":"Johnson","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1200\/OP.21.00624","article-title":"All you need to know about UGT1A1 genetic testing for patients treated with Irinotecan: a practitioner-friendly guide","volume":"18","author":"Karas","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"B25","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"103706","DOI":"10.1016\/j.clon.2024.103706","article-title":"Pharmacogenomics: DPYD and prevention of toxicity","volume":"38","author":"Keen","year":"2025","journal-title":"Clin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.928","article-title":"PharmCAT: a pharmacogenomics clinical annotation tool","volume":"104","author":"Klein","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"692234","DOI":"10.3389\/fgene.2021.692234","article-title":"CYP2B6 functional variability in drug metabolism and exposure across populations\u2014implication for drug safety, dosing, and individualized therapy","volume":"12","author":"Langmia","year":"2021","journal-title":"Front. Gen."},{"key":"B28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41525-022-00283-3","article-title":"Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic exome sequencing data","volume":"7","author":"Lanillos","year":"2022","journal-title":"Npj Genomic Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41397-023-00322-x","article-title":"Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity","volume":"24","author":"Larrue","year":"2024","journal-title":"Pharmacogenomics J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1002\/cpt.2122","article-title":"Pharmacogenetics at scale: an analysis of the UK biobank","volume":"109","author":"McInnes","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e70246","DOI":"10.1111\/cts.70246","article-title":"Frequency and implications of high\u2010risk pharmacogenomic phenotypes identified in a diverse Australian pediatric oncology cohort","volume":"18","author":"Moore","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/molbev\/msw249","article-title":"Genome-wide analysis in Brazilians reveals highly differentiated native American genome regions","volume":"34","author":"Mychaleckyj","year":"2017","journal-title":"Mol. Biol. Evol. msw249"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/s41467-022-28648-3","article-title":"Whole-genome sequencing of 1,171 elderly admixed individuals from Brazil","volume":"13","author":"Naslavsky","year":"2022","journal-title":"Nat. Commun."},{"key":"B34","article-title":"NCCN clinical practice guideline in oncology: colon cancer (No. Version 5)","year":"2025","journal-title":"Natl. Compr. Cancer Netw. NCCN"},{"key":"B35","unstructured":"NHS England \u00bb national genomic test directory\n          \n          \n          2025"},{"key":"B36","doi-asserted-by":"publisher","first-page":"eadl3564","DOI":"10.1126\/science.adl3564","article-title":"Admixture\u2019s impact on Brazilian population evolution and health","volume":"388","author":"Nunes","year":"2025","journal-title":"Science"},{"key":"B37","unstructured":"Gene-specific information tables for CYP3A5\n          \n          \n          2025"},{"key":"B38","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jmoldx.2023.06.008","article-title":"CYP3A4 and CYP3A5 genotyping recommendations","volume":"25","author":"Pratt","year":"2023","journal-title":"J. Mol. Diagn."},{"key":"B39","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/clpt.2014.125","article-title":"The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update","volume":"96","author":"Ramsey","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature15817","article-title":"Pharmacogenomics in the clinic","volume":"526","author":"Relling","year":"2015","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT 15 genotypes: 2018 update","volume":"105","author":"Relling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/ajhb.22714","article-title":"Meta\u2010analysis of Brazilian genetic admixture and comparison with other Latin America countries","volume":"27","author":"Rodrigues De Moura","year":"2015","journal-title":"Am. J. Hum. Biol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0231651","DOI":"10.1371\/journal.pone.0231651","article-title":"Identification of NUDT15 gene variants in Amazonian Amerindians and admixed individuals from northern Brazil","volume":"15","author":"Rodrigues","year":"2020","journal-title":"PLOS ONE"},{"key":"B44","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/01.GIM.0000153664.65759","article-title":"CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnetTM systematic review and meta-analysis","volume":"7","author":"Sanderson","year":"2005","journal-title":"Genet. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/cpt.1568","article-title":"Pharmacogenomics clinical annotation tool (Pharm CAT)","volume":"107","author":"Sangkuhl","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10549-024-07474-9","article-title":"Genetic variants and social benefit receipt in premenopausal women with breast cancer treated with docetaxel: a Danish population-based cohort study","volume":"209","author":"Schmidt","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1350162","DOI":"10.3389\/fonc.2024.1350162","article-title":"Mapping breast and prostate cancer in the Brazilian public health system: study protocol of the onco-genomas Brasil","volume":"14","author":"Schuch","year":"2024","journal-title":"Front. Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","volume":"94","author":"Scott","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"13900","DOI":"10.1038\/s41598-019-50362-2","article-title":"Distribution of local ancestry and evidence of adaptation in admixed populations","volume":"9","author":"Secolin","year":"2019","journal-title":"Sci. Rep."},{"key":"B50","doi-asserted-by":"publisher","first-page":"106527","DOI":"10.1016\/j.ejps.2023.106527","article-title":"In vitro identification of decreased function phenotype ABCG2 variants","volume":"188","author":"Suominen","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/clpt.2013.229","article-title":"Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing","volume":"95","author":"Van Driest","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00280-019-03905-3","article-title":"Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes","volume":"84","author":"Van Eijk","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/phar.2463","article-title":"DPYD and UGT1A1 pharmacogenetic testing in patients with gastrointestinal malignancies: an overview of the evidence and considerations for clinical implementation","volume":"40","author":"Varughese","year":"2020","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1200\/JCO.2014.59.4671","article-title":"Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia","volume":"33","author":"Yang","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fgene.2013.00024","article-title":"Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance","volume":"4","author":"Zanger","year":"2013","journal-title":"Front. Genet."},{"key":"B56","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41397-022-00288-2","article-title":"The genetic landscape of major drug metabolizing cytochrome P450 genes\u2014an updated analysis of population-scale sequencing data","volume":"22","author":"Zhou","year":"2022","journal-title":"Pharmacogenomics J."},{"key":"B57","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40246-023-00461-z","article-title":"Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences","volume":"17","author":"Zhou","year":"2023","journal-title":"Hum. Genomics"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1736887\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T06:35:52Z","timestamp":1772433352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1736887\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":58,"alternative-id":["10.3389\/fphar.2026.1736887"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1736887","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"article-number":"1736887"}}